For the first time in the world, a drug that can be used in the treatment of patients with obsessive compulsive disorder was developed by artificial intelligence. With the help of artificial intelligence, it is predicted that drug development in the future will become faster and more efficient. According to the news in the Euroean Pharmaceuitical Review, the first non-human drug molecule, DSP-1181, entered the first stage clinical trials. The artificial intelligence that developed the drug was developed by Sumitomo Dainippon Pharma from Japan and Exscienta from the UK. Developed by two companies, this artificial intelligence managed to develop the component, which normally takes 5 years to develop, in just 12 months.